science1 publisher
Off-label GLP-1 prescribing reaches one in eleven US children aged 8 to 11 with obesity
Prescribing has outrun the approval label for US children aged 8 to 11 with obesity. The trial behind the benefit claim followed them for 68 weeks. Those 68 weeks are the entire developmental record so far.
Publishers:newscientist.com
Reality
- Evidence50
- Adoption72
- Hype gap+14
- Incentives62
- Confidence55